A mysterious turn in the phase IIb story with idiopathic pulmonary fibrosis (IPF) candidate bexotegrast sent shares of Pliant Therapeutics Inc. (NASDAQ:PLRX) down 60.6%, or $4.72, to close Feb. 10 at $3.07.
CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China of SYH-2059 tablets for interstitial lung disease, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Puretech Health plc has announced phase IIb data showing its reformulation of pirfenidone has improved the tolerability and increased the efficacy of the marketed antifibrotic in the treatment of idiopathic pulmonary fibrosis. The tweak on the original molecule involved substituting three hydrogen atoms with three of the heavier counterpart, deuterium, improving stability, whilst retaining the antifibrotic effect.
News that Trevi Therapeutics Inc. got the size just right of the phase IIb Coral trial with Haduvio (oral nalbuphine extended release) led the company’s shares (NASDAQ:TRVI) to close Dec. 12 at $3.60, up $1.11, or 45%, after trading as high as $4.60.
Haisco Pharmaceutical Group Co. Ltd. has described compounds acting as integrin αvβ1 and/or αvβ6 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
TRAF2- and NCK-interacting kinase (TNIK) has been reported as a therapeutic target for colorectal cancer and, more recently, for lung squamous cell carcinoma, triple-negative breast cancer, or ovarian cancer, among others, especially in combination with inhibiting cancer-related kinases.
Tankyrases (TNKS) are involved in relevant cellular functions such as telomere maintenance or Wnt signaling, and their inhibition may be a potential treatment strategy for the management of hyperproliferative disorders because it counteracts profibrotic changes and blocks the synthesis of extracellular matrix proteins.
Haisco Pharmaceutical Group Co. Ltd. has disclosed integrin αvβ1 and/or integrin αvβ6 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
